BSX — Claude Opus 4.8

I'll research Boston Scientific (BSX) before writing the preview. Let me gather recent earnings materials, transcripts, and news.The stock data reveals a dramatic story — BSX has fallen ~50% from January highs. Let me dig into the recent earnings materials and the restructuring news.Now let me read the restructuring 8-K and the prior-year Q2 2025 release for comp context, plus recent news.Let me pull the Q4 2025 release to capture the original 2026 guidance, and compute price stats.# Boston Scientific (BSX) — Q2 2026 Earnings Preview

Report expected: Wednesday, July 29, 2026 (before market open) | 2026Q2 Earnings Call

The one-line setup

BSX has gone from Street darling to "show-me" story in the span of six months. After a decade of consistently beating-and-raising, management cut full-year guidance in April, the stock has roughly halved year-to-date, and — just days before this print — the company pre-announced a large global restructuring. Tomorrow is about whether the reset guidance is finally the floor.

Stock context: a brutal de-rating

BSX is down ~51% year-to-date (from ~$95 in early January to ~$46 on July 28) and ~53% off its January 7 high of ~$98.65. This dramatically underperforms the S&P 500 (roughly flat to modestly up over the period) and peers like Abbott and Medtronic.
Two step-downs drove most of the damage: a ~-18% gap on Feb 4 (Q4'25 print / initial 2026 guide) and continued erosion after the April 22 guidance cut.
The shares have stabilized recently, bouncing ~8% off the late-June low near $43. Sentiment is decidedly negative heading in — per pre-earnings commentary, the Street models ~5.3% organic growth and $0.83 EPS, essentially in line with guidance, with worries centered on electrophysiology, WATCHMAN, urology, and FARAPULSE share loss.

Implication: Expectations are washed out. The bar for a relief rally is low — an in-line quarter with a maintained full-year guide could be enough. But another guide-down would confirm the bear case that the long-range plan (LRP) is broken.

How we got here: the 2026 guidance journey

Milestone	FY26 Organic Growth	FY26 Adj. EPS
Initial guide (Feb 4, w/ Q4'25)	10.0–11.0%	$3.43–$3.49
Revised guide (Apr 22, w/ Q1'26)	6.5–8.0%	$3.34–$3.41 (+9–11%)

The April cut was notable because Q1 itself was fine — +9.4% organic (high end of guide) and $0.80 adjusted EPS (high end). Management (Mahoney called it "not my happiest moment") attributed the reduction to three areas:

WATCHMAN — a mid-February inflection where strong concomitant (with-ablation) demand was offset by decelerating stand-alone implants, pressured by hospital capacity, procedure prioritization, a shift of cases from interventional cardiologists to EPs, and reimbursement dynamics.
Electrophysiology / FARAPULSE — more PFA share erosion than expected as Medtronic, J&J, and now Abbott intensify competition in the U.S.
Urology — a weak +1% organic Q1, driven by stone management (China VBP + product gaps) and ongoing sacral neuromodulation (SNM) commercial disruption.

Management framed Q2 as "the toughest quarter of the year" due to very difficult sequential dollar comps in EP and WATCHMAN, plus transient endoscopy supply-chain issues — with improvement expected in 2H.

What Q2 2026 guidance implies

Metric	Q2 2026 Guide	Q2 2025 Actual (comp)
Reported revenue growth	5.5–7.5%	+22.8%
Organic revenue growth	5.0–7.0%	+17.4%
Adjusted EPS	$0.82–$0.84	$0.75
Implied revenue	~$5.34–5.44B	$5.061B

Note the very tough prior-year comp: Q2'25 was BSX's peak, with +17.4% organic and a big U.S. beat (+30.7% reported). The EPS guide still implies ~9–12% growth despite the top-line slowdown, reflecting aggressive cost control.

The key debates for tomorrow

1. Is the guide the floor, or is another cut coming?

This is the whole ballgame. Given the April reset and the pre-announced restructuring, watch closely whether management holds, trims, or "kitchen-sinks" the FY26 organic range (6.5–8%). Holding the line — especially with a Q2 at or above the 5–7% organic guide — would be a meaningful confidence signal.

2. The restructuring pre-announcement (July 21/27)

Just ahead of the print, the Board approved a 2026 Restructuring Plan: $700–800M in pre-tax charges (transfer costs, termination benefits) with ~$500M of gross annual pre-tax savings, substantially complete by 2029. Crucially, "a substantial portion of the savings [is] expected to be reinvested in strategic growth initiatives." - Bull read: protects the double-digit EPS algorithm and 150 bps of LRP margin expansion even if top-line stays sub-trend. - Bear read: cutting into a slowdown signals management no longer sees the revenue snap-back it once did. Watch how much savings actually drops to the bottom line vs. gets reinvested.

3. Electrophysiology / FARAPULSE — the most important number

BSX guided global EP ~10% for FY26, with U.S. mid-single-digit (implying roughly flat U.S. sequentially 2Q–4Q) and international ~+20%. The market is watching for evidence BSX is stabilizing PFA share against MDT/JNJ/ABT. Any incremental U.S. share commentary — and updates on the pipeline (next-gen FARAWAVE, FARAPOINT ramp, Faraflex, mapping/OPAL adoption) — will move the stock.

4. WATCHMAN — stand-alone vs. concomitant

FY guide is global mid-teens / U.S. low-to-mid-teens (down from ~30% growth in 2025). Investors want confirmation that (a) stand-alone declines are stabilizing, and (b) the positive CHAMPION-AF data (met all primary/secondary endpoints, presented at ACC / published in NEJM) is starting to translate into label/guideline momentum and reaccelerating volumes. Concomitant is ~25% of procedures today, targeted to reach ~50% over the LRP.

5. Urology recovery

Look for sequential improvement from the +1% Q1 trough as the SNM sales force is rebuilt (~100 reps hired/training) and new products launch (Asurys, eCoin/Valencia, slim ureteroscope). FY expectation was reset to low-to-mid single digits — below-market for BSX.

6. Margins, cash, and buyback

FY26 adjusted operating margin still guided to +50–75 bps, but gross margin now expected slightly below 2025 (tariffs, POLARx discontinuation, less mix benefit) — so the story is now an OpEx-leverage / cost-out story, not gross-margin expansion.
FY26 FCF guided ~$4B; leverage 1.8x; tax ~12%.
Management said it intended to repurchase ~$2B of stock in Q2 (its first buyback in years) once out of the Penumbra-related blackout — watch for confirmation it bought back aggressively at depressed prices, a signal of conviction.

7. Penumbra (~$15B) integration

The deal cleared the Penumbra shareholder vote (early May) and was expected to close in 2H26. Watch for updated closing timing, financing/accretion commentary, and reassurance the deal economics still work after BSX's own equity de-rated.

8. The LRP question

On the Q1 call, management backed away from the prior "10%+" LRP top-line target (now framed as "likely an upside scenario"), while reaffirming ~150 bps of margin expansion and double-digit EPS growth through the plan. Any refresh of long-term revenue framing — and confidence in a 2027 reacceleration (easier comps + product launches) — is a key swing factor for the multiple.

What would move the stock

Bullish signals - Q2 organic at/above the 5–7% guide; FY26 guide maintained or raised - U.S. EP stabilizing; WATCHMAN stand-alone inflecting positive - Restructuring savings largely flowing to EPS; buyback executed near lows - Confident 2027 reacceleration narrative

Bearish signals - Another FY guide cut or a Q2 miss on the (already lowered) bar - Continued U.S. PFA share loss / no WATCHMAN stabilization - Gross-margin pressure worse than flagged; savings fully reinvested (no EPS flow-through) - Softer/uncertain Penumbra close or LRP commentary

Bottom line

BSX enters this print as a fallen compounder trading near multi-year relative lows, with a heavily de-risked guide and a fresh restructuring aimed at defending its double-digit EPS algorithm. The fundamental questions — can it stabilize PFA share, re-accelerate WATCHMAN, and fix Urology — won't be fully answered in one quarter. But with sentiment this negative and the Street essentially modeling in-line with guidance, the asymmetry favors a relief move if management simply holds the line and points credibly to a 2027 recovery. The biggest risk is a third negative surprise in a row, which would call the LRP — and the "premium med-tech grower" thesis — into serious question.

Note: This preview is based on company filings, transcripts, and market data through July 28, 2026, and is for informational purposes only — not investment advice.